NEW STUDY: 8 patients taking 1000 mg/d nicotinamide riboside (NR) for a month saw improvements in brain vasculature & cognition.
What’s the evidence NAD boosters improve blood flow and cognition in humans? 🧠🧵
2
In 2018-19, we and Zoltan Ungvari’s lab showed that mice treated with an NAD booster (NMN) had better blood flow in muscle & brain, with greater endurance & cognition
3
In this new study, peripheral artery disease (PAD) patients took 1000 mg of NR in the morning for 4 weeks
4
An earlier study using only 250 mg NMN (a similar NAD booster) failed to see strong statistical improvements in vascular function in humans but there were trends and this dose was too low. 1000 mg would have been a smarter trial nature.com/articles/s4159…
5
That study found that 12-week supplementation with 250 mg NMN tended to reduce pulse wave velocity values, baPWV (a measure of arterial stiffness)
6
A previous meta-analysis of longitudinal cohort studies investigating baPWV showed that the risk of cardiovascular events associated with high baPWV is almost three times that associated with low baPWV
7
One clinical trial report reported similar results with NR. In that study, a 6-week supplementation with 1000 mg/day of NR tended to reduce carotid-femoral PWV in healthy middle-aged and older people
8
Promising results and all pointing in the same direction as our mouse data. Thus, NR and NMN supplementation may alleviate vascular stiffness and reduce the risk of CVD events
9
This is our 🐁 study from 2018 showing improved vascular function and endurance in muscle of mice treated with NMN cell.com/cell/fulltext/…
10
Here’s the study with Prof. Ungvari and team in 2019 of cerebral vascular function and improved memory in mice sciencedirect.com/science/articl…
11
These new findings indicate that NAD+ supplementation holds promise as a therapeutic strategy for enhancing endothelial function in older adults with PAD and for preventing or delaying vascular complications, including cognitive impairment
12
Further research is warranted to confirm these benefits and explore the broader implications of NAD+ supplementation for promoting vascular and cognitive health
13
The small sample size limits the generalizability of the findings, but will guide the design of larger, more extended, and more robust studies with greater statistical power
14
Encouraged by these initial results, the authors are motivated to pursue studies with more substantial sample sizes to detect even smaller, yet clinically significant changes